Effect of PEG surface conformation on anticancer activity and blood circulation of nanoemulsions loaded with tocotrienol-rich fraction of palm oil

AAPS Journal

Volumn 15, Issue 4, 2013, Pages 1168-1179

  Alayoubi, Alaadin ^a   Alqahtani, Saeed ^a   Kaddoumi, Amal ^a   Nazzal, Sami ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

nanoemulsion; PEG2000 DSPE; PEGylation; poloxamer; tocotrienol

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [AMINO(POLYETHYLENE GLYCOL)2000] DSPE; ALPHA TOCOTRIENOL; MACROGOL 2000; PALM OIL; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CELL TRANSPORT; CIRCULATION TIME; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SENSITIVITY; DRUG STABILITY; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NANOEMULSION; NONHUMAN; PHYSICAL STRESS; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMULSIONS; HUMANS; MALE; MCF-7 CELLS; NANOTECHNOLOGY; PLANT OILS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; TOCOTRIENOLS;

EID: 84887994216     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9525-z     Document Type: Article

References (63)

1. Sylvester PW, Kaddoumi A, Nazzal S, El Sayed KA. The value of tocotrienols in the prevention and treatment of cancer. J Am Coll Nutr. 2010;29(3 Suppl):324S-33S.
2. Nesaretnam K, Meganathan P, Veerasenan SD, Selvaduray KR. Tocotrienols and breast cancer: the evidence to date. Genes Nutr. 2012;7(1):3-9. doi: 10.1007/s12263-011-0224-z.
3. Kannappan R, Gupta SC, Kim JH, Aggarwal BB. Tocotrienols fight cancer by targeting multiple cell signaling pathways. Genes Nutr. 2012;7(1):43-52. doi: 10.1007/s12263-011-0220-3.
4. Yap SP, Yuen KH, Lim AB. Influence of route of administration on the absorption and disposition of alpha-, gamma- and delta-tocotrienols in rats. J Pharm Pharmacol. 2003;55(1):53-8. doi: 10.1211/002235702450.
5. Sen CK, Khanna S, Roy S. Tocotrienols: vitamin E beyond tocopherols. Life Sci. 2006;78(18):2088-98. doi: 10.1016/j.lfs.2005.12.001.
6. Alqahtani S, Alayoubi A, Nazzal S, Sylvester P, Kaddoumi A. Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilic molecules: in vivo and in vitro studies. AAPS J. 2013;1-12. doi: 10.1208/s12248-013-9481-7.
7. Goppert TM, Muller RH. Plasma protein adsorption of Tween 80- and poloxamer 188-stabilized solid lipid nanoparticles. J Drug Target. 2003;11(4):225-31. doi: 10.1080/10611860310001615956QPXLM2E4EJ3LJL2B.
8. Le UM, Cui Z. Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm. 2006;312(1-2):105-12. doi: 10.1016/j.ijpharm.2006.01.002.
9. Soundararajan A, Bao A, Phillips WT, Perez R, Goins BA. [186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol. 2009;36(5):515-24.
10. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463-78.
11. Maruyama K, Yuda T, Okamoto A, Kojima S, Suginaka A, Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta. 1992;1128(1):44-9.
12. Moghimi SM. Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo? Biochim Biophys Acta Gen Subj. 1997;1336(1):1-6.
13. Alayoubi A, Nazzal M, Sylvester PW, Nazzal S. "Vitamin E" fortified parenteral lipid emulsions: Plackett-Burman screening of primary process and composition parameters. Drug Dev Ind Pharm. 2012. doi: 10.3109/03639045.2012.682223.
14. Alayoubi AY, Anderson JF, Satyanarayanajois SD, Sylvester PW, Nazzal S. Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcinoma cells. Eur J Pharm Sci. 2013;48(3):385-92.
15. Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C, et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine. 2010;6(1):170-8. doi: 10.1016/j.nano.2009.05. 004S1549-9634(09)00097-5.
16. Harvie P, Wong FMP, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci. 2000;89(5):652-63. doi: 10.1002/(sici)1520- 6017(200005)89:5<652::aid-jps11>3.0.co;2-h.
17. Han J, Davis SS, Washington C. Physical properties and stability of two emulsion formulations of propofol. Int J Pharm. 2001;215(1-2):207-20.
18. Xu A, Yao M, Xu G, Ying J, Ma W, Li B, et al. A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants. Int J Nanomedicine. 2012;7:3547-54. doi: 10.2147/IJN.S32188ijn-7- 3547.
19. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6(4):662-8. doi: 10.1021/nl052396o.
20. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713-22. doi: 10.1016/j.biomaterials.2004.07.050.
21. Huang J, Bu L, Xie J, Chen K, Cheng Z, Li X, et al. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone- coated iron oxide nanoparticles. ACS Nano. 2010;4(12):7151-60. doi: 10.1021/nn101643u.
22. Jumaa M, Müller BW. Development of a novel parenteral formulation for tetrazepam using a lipid emulsion. Drug Dev Ind Pharm. 2001;27(10):1115-21. doi: 10.1081/DDC-100108374.
23. Bock TK, Müller BW. A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems. Pharm Res. 1994;11(4):589-91. doi: 10.1023/a:1018987120738.
24. Jumaa M, Kleinebudde P, Müller BW. Physicochemical properties and hemolytic effect of different lipid emulsion formulations using a mixture of emulsifiers. Pharm Acta Helv. 1999;73(6):293-301. doi: 10.1016/s0031-6865(99) 00003-5.
25. Abuasal B, Thomas S, Sylvester PW, Kaddoumi A. Development and validation of a reversed-phase HPLC method for the determination of gamma-tocotrienol in rat and human plasma. Biomed Chromatogr. 2011;25(5):621-7. doi: 10.1002/bmc.1493.
26. Gao K, Sun J, Liu K, Liu X, He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm. 2008;34(11):1227-37. doi: 10.1080/03639040802005057.
27. Han J, Davis SS, Papandreou C, Melia CD, Washington C. Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability. Pharm Res. 2004;21(9):1573-80. doi: 10.1023/b:pham. 0000041451.70367.21.
28. Ilium L, Davis SS, Wilson CG, Thomas NW, Frier M, Hardy JG. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int J Pharm. 1982;12(2-3):135-46.
29. Ishii F, Nagasaka Y. Interaction between erythrocytes and free phospholipids as an emulsifying agent in fat emulsions or drug carrier emulsions for intravenous injections. Colloids Surf B: Biointerfaces. 2004;37(1-2):43-7. doi: 10.1016/j.colsurfb.2004.05.016.
30. Bjerregaard S, Wulf-Andersen L, Stephens RW, Røge Lund L, Vermehren C, Söderberg I, et al. Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin. J Control Release. 2001;71(1):87-98. doi: 10.1016/s0168-3659(00)00370-9.
31. El-Hariri LM, Marriott C, Martin GP. The mitigating effects of phosphatidylcholines on bile salt- and lysophosphatidylcholine-induced membrane damage. J Pharm Pharmacol. 1992;44(8):651-4. doi: 10.1111/j.2042-7158.1992. tb05487.x.
32. Forster D, Washington C, Davis SS. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol. 1988;40(5):325-8. doi: 10.1111/j.2042-7158.1988.tb05260.x.
33. Weingarten C, Santos Magalhaes NS, Baszkin A, Benita S, Seiller M. Interactions of a non-ionic ABA copolymer surfactant with phospholipid monolayers: possible relevance to emulsion stabilization. Int J Pharm. 1991;75(2-3):171-9. doi: 10.1016/0378-5173(91)90191-p.
34. Lechmann T, Reinhart WH. The non-ionic surfactant Poloxamer 188 (RheothRx®) increases plasma and whole blood viscosity. Clin Hemorheol Microcirc. 1998;18(1):31-6.
35. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34. doi: 10.1016/j.jconrel.2012.03.020S0168- 3659(12)00230-1.
36. Goppert TM, Muller RH. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur J Pharm Biopharm. 2005;60(3):361-72. doi: 10.1016/j.ejpb.2005.02.006.
37. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-13.
38. Schmidt S, Muller RH. Plasma protein adsorption patterns on surfaces of amphotericin B-containing fat emulsions. Int J Pharm. 2003;254(1):3-5.
39. Patil S, Sandberg A, Heckert E, Self W, Seal S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28(31):4600-7.
40. Lu X, Howard MD, Mazik M, Eldridge J, Rinehart JJ, Jay M, et al. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: optimization and in vitro characterization. AAPS J. 2008;10(1):133-40. doi: 10.1208/s12248-008-9013-z.
41. Gessner A, Waicz R, Lieske A, Paulke B, Mader K, Muller RH. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm. 2000;196(2):245-9.
42. Perry JL, Reuter KG, Kai MP, Herlihy KP, Jones SW, Luft JC, et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 2012;12(10):5304-10. doi: 10.1021/nl302638g.
43. Zhang G, Zeng X, Li P. Nanomaterials in cancer-therapy drug delivery system. J Biomed Nanotechnol. 2013;9(5):741-50. doi: 10.1166/jbn.2013.1583.
44. Tsoneva I, Iordanov I, Berger AJ, Tomov T, Nikolova B, Mudrov N, et al. Electrodelivery of drugs into cancer cells in the presence of poloxamer 188. J Biomed Biotechnol. 2010;2010:11. doi: 10.1155/2010/314213.
45. Alayoubi A, Kanthala S, Satyanarayanajois SD, Anderson JF, Sylvester PW, Nazzal S. Stability and in vitro antiproliferative activity of bioactive "Vitamin E" fortified parenteral lipid emulsions. Colloids Surf B: Biointerfaces. 2013;103(0):23-30.
46. Wang SH, Lee CW, Chiou A, Wei PK. Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images. J Nanobiotechnology. 2010;8:33. doi: 10.1186/1477-3155-8-331477-3155-8- 33.
47. Zhang Y, Tang L, Sun L, Bao J, Song C, Huang L, et al. A novel paclitaxel-loaded poly(ε-caprolactone)/poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 2010;6(6):2045-52.
48. Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. A novel docetaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett. 2009;4(12):1530-9. doi: 10.1007/s11671-009-9431-61556-276X-4-1530.
49. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007;130(4):601-10. doi: 10.1016/j.cell.2007.08.006.
50. dit Faute MA, Laurent L, Ploton D, Poupon MF, Jardillier JC, Bobichon H. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis. 2002;19(2):161-8.
51. Schutte M, Fox B, Baradez MO, Devonshire A, Minguez J, Bokhari M, et al. Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. Assay Drug Dev Technol. 2011;9(5):475-86. doi: 10.1089/adt.2011.0371.
52. Knight E, Murray B, Carnachan R, Przyborski S. Alvetex(R): polystyrene scaffold technology for routine three dimensional cell culture. Methods Mol Biol. 2011;695:323-40. doi: 10.1007/978-1-60761-984-0-20.
53. Katza E, Hadlington-Boothb W, Fauvinc D, Rettenbergerb P. Incorporating the extracellular matrix: new opportunities in cancer research. Development. 2007;134(23):4177-86.
54. Reinnervate. Routine assessment of cancer cell cytotoxicity in a novel three dimensional culture assay. Application note 2 2013.
55. Shirode AB, Sylvester PW. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother. 2010;64(5):327-32. doi: 10.1016/j.biopha.2009.09.018.
56. Bachawal SV, Wali VB, Sylvester PW. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer. 2010;10:84. doi: 10.1186/1471-2407-10-84.
57. Wali VB, Sylvester PW. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids. 2007;42(12):1113-23. doi: 10.1007/s11745-007-3102-0.
58. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 2000;18(10):412-20.
59. Woodle MC, Storm G. Long circulating liposomes: old drugs, new therapeutics. Austin: Landes; 1998.
60. Wang R, Xiao R, Zeng Z, Xu L, Wang J. Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery. Int J Nanomedicine. 2012;7:4185-98. doi: 10.2147/IJN.S34489ijn-7-4185.
61. Tan B, Watson RR, Preedy VR. Tocotrienols: vitamin E beyond tocopherols. Boca Raton: CRC; 2012.
62. Louguet S, Kumar AC, Guidolin N, Sigaud G, Duguet E, Lecommandoux S, et al. Control of the PEO chain conformation on nanoparticles by adsorption of PEO-block-poly(l-lysine) copolymers and its significance on colloidal stability and protein repellency. Langmuir. 2011;27(21):12891-901. doi: 10.1021/la202990y.
63. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 2007;1768(6):1367-77. doi: 10.1016/j.bbamem.2006.12.013.